AI-ENHANCED GENETIC TESTING FOR PERSONALIZED CANCER THERAPY

ABSTRACT

This article discusses the integration of AI-enhanced genetic testing in personalized cancer therapy. Genetic profiling technologies combined with artificial intelligence have opened new dimensions in oncology by enabling tailored treatment strategies based on individual genetic variations. The focus is on how AI aids in the interpretation of genetic data, supports treatment decisions, and enhances non-invasive diagnostic approaches. The article highlights implications for Kazakhstan and other regions with growing cancer burdens and emphasizes the role of cutting-edge technologies in improving outcomes and equity in cancer care.

Keywords: artificial intelligence; genetic testing; personalized therapy; oncology; cancer treatment.

INTRODUCTION

Cancer treatment has significantly evolved with the advent of personalized therapy, which tailors interventions based on individual genetic profiles. While traditional therapies relied on generalized protocols, current approaches seek precision using genetic information. The development of next-generation sequencing (NGS) and liquid biopsy methods has accelerated this transformation. However, the interpretation of complex genomic data poses challenges for clinicians. This article explores how artificial intelligence technologies can bridge that gap by supporting analysis and treatment planning.

In Kazakhstan, the increasing incidence of cancer and the need for efficient healthcare interventions make this topic especially relevant. Integrating AI into genetic oncology offers a means to enhance diagnostic accuracy, optimize therapy, and reduce unnecessary exposure to ineffective treatments.

TECHNOLOGICAL INNOVATIONS AND CLINICAL INTEGRATION

Modern genetic testing technologies, such as whole-exome sequencing and targeted panels, detect inherited and somatic mutations. These tests identify mutations in genes like BRCA1/2, EGFR, and KRAS, which can guide targeted therapy. AI algorithms process vast datasets to uncover correlations between genetic variants and treatment outcomes, enabling personalized strategies.

One emerging tool is the AI-driven liquid biopsy, which analyzes circulating tumor DNA from blood samples. This approach allows for non-invasive diagnostics and real-time monitoring. In the UK, trials of such AI-assisted tests have shown over 99% accuracy in detecting multiple cancer types, suggesting their future potential for global implementation. AI also supports clinical decision-making by ranking treatment options based on predicted efficacy and patient-specific factors. Dashboards and digital platforms visualize genomic data, making it accessible to clinicians and facilitating interdisciplinary collaboration.

ETHICAL AND PRACTICAL CHALLENGES

While the benefits are substantial, ethical and logistical concerns must be addressed. These include data privacy, informed consent, and algorithmic transparency. Machine learning systems should undergo rigorous validation to prevent biased or incorrect recommendations.

Accessibility remains a key challenge. In many regions, including parts of Kazakhstan, disparities in healthcare infrastructure limit access to genetic testing. Public education and government support are critical for promoting widespread adoption and ensuring equitable benefits.

FUTURE OUTLOOK AND RELEVANCE

The future of cancer care will increasingly depend on the synergy between AI and molecular diagnostics. Kazakhstan, with its investments in medical modernization, can play a pivotal role by adopting AI-enhanced genetic testing platforms. These tools can improve early detection, personalize therapy, and ultimately reduce cancer mortality.

This integration supports Kazakhstan's health strategy and aligns with international goals such as those promoted by the WHO and IAEA. The potential for innovation in cancer care offers a path forward that is not only scientifically promising but also socioeconomically essential.

CONCLUSION

AI-enhanced genetic testing represents a transformative step in personalized oncology. By enabling precise, efficient, and accessible cancer care, it supports both medical advancement and public health goals. With appropriate support, these technologies can benefit not only developed nations but also emerging healthcare systems like Kazakhstan's.

References:

1. Invitae. (2024). Personalize cancer treatment with genetic testing. Retrieved from https://www.invitae.com/us/providers/oncology/personalize-cancer-treatment
2. GlobalRPH. (2025). Genetic Testing for Cancer: New Evidence Questions Universal Screening Protocol. Retrieved from https://globalrph.com/2025/03/genetic-testing-for-cancer
3. The Times. (2025). Blood test for bowel cancer to be trialled on NHS. Retrieved from https://www.thetimes.co.uk/article/blood-test-for-bowel-cancer
4. AAMC. (2023). Personalized medicine is coming — who will have access to it? Retrieved from https://www.aamc.org/news/personalized-medicine-coming-who-will-have-access-it
5. Straits Research. (2025). Cancer Genetic Testing Market Size to Reach USD 17.98 Billion by 2033. Retrieved from https://www.globenewswire.com/news-release/2025/01/30